NCT07309419 2025-12-30
Cocktail-001
Shanghai Zhongshan Hospital
Phase 2/3 Not yet recruiting
Clinical Trials
8 trialsNCT03759093 2023-09-06
CURATE.AI Optimized Modulation for Multiple Myeloma
National University Hospital, Singapore
Phase 2/3 Unknown
NCT04453345 2020-07-01
TPM Regimen (Thalidomide, Prednisone and Methotrexate) in LGLL
Institute of Hematology & Blood Diseases Hospital, China
Phase 2/3 Unknown
NCT00657488 2019-10-18
Thalidomide 100 mg/Day Versus Thalidomide 400 mg/Day in Relapse Refractory Multiple Myeloma
Celgene
Phase 2/3 Completed
NCT00038090 2018-10-31
Thalidomide-Dexamethasone for Multiple Myeloma
M.D. Anderson Cancer Center
Phase 2/3 Completed
NCT02387086 2015-03-12
Gefitinib Combined With Thalidomide to Treat NSCLC
Shaanxi Provincial People's Hospital
Phase 2/3 Unknown
NCT00934739 2015-02-25
A Study of High-Risk Oral Cavity Cancer
National Health Research Institutes, Taiwan
Phase 2/3 Terminated
NCT00205751 2013-11-25
Thalidomide/Dexamethasone vs MP for Induction Therapy and Thalidomide/Intron A vs Intron A for Maintenance Therapy
Austrian Forum Against Cancer
Phase 2/3 Completed